Glycans are ubiquitous components of all organisms. Efforts to elucidate glycan function and to understand how they are assembled and disassembled can reap benefits in fields ranging from bioenergy to human medicine. Significant advances in our knowledge of glycan biosynthesis and function are emerging, and chemical biology approaches are accelerating the pace of discovery. Novel strategies for assembling oligosaccharides, glycoproteins, and other glycoconjugates are providing access to critical materials for interrogating glycan function. Chemoselective reactions that facilitate the synthesis of glycan-substituted imaging agents, arrays, and materials are yielding compounds to interrogate and perturb glycan function and dysfunction. To complement these advances, small molecules are being generated that inhibit key glycan-binding proteins or biosynthetic enzymes. These examples illustrate how chemical glycobiology is providing new insight into the functional roles of glycans and new opportunities to interfere with or exploit these roles.
INTRODUCTION
Glycans, which are compounds that include monosaccharides, oligosaccharides, polysaccharides, and their conjugates, are critical constituents of all organisms. Members of a glycan subset, the polysaccharides, are the most abundant organic compounds on Earth. Glycoconjugates (e.g., peptidoglycan, glycolipids, glycoproteins) also are prevalent. In humans, for example, half of all proteins are glycosylated (1) . Consistent with glycan abundance in nature, data from genomic sequencing indicate that approximately 1% of each genome, from eubacteria to archea and eukaryotes, is dedicated to sugar-processing enzymes (2) . Moreover, these genes can be highly conserved, as the components of few other biochemical pathways are so invariant as those responsible for glycan biosynthesis (3) . The importance of this conservation is underscored by data indicating that defects in the glycan biosynthetic machinery in humans, known as congenital disorders of glycosylation, are rare and generally have severe deleterious consequences (4) .
Genomic analysis is a powerful means to identify enzymes that generate or degrade glycans and the proteins that recognize the glycan products. Still, it does not reveal what glycans are present in a cell or organism because the synthesis of glycans is not template directed. As a result, elucidating the molecular mechanisms that underlie glycan function has been a challenge. Nevertheless, researchers have uncovered numerous roles for glycans, including those in fertilization and development, hormone function, cell proliferation and organization, host-pathogen interactions, and the inflammatory and immune responses (3) . These findings are providing additional impetus to devise new approaches that meet the challenges of elucidating and manipulating glycan function.
The increased appreciation for the ubiquity of glycans and their importance to human health has spawned the field of chemical glycobiology. Because of the complexities of glycans, their study has compelled researchers to pursue interdisciplinary approaches. Since the pioneering contributions of 1902 Nobel Laureate Emil Fischer, it has been apparent that our understanding of glycan function can be advanced using approaches that span biology and chemistry. The nucleation of the discipline of chemical biology is yielding new and innovative strategies to probe glycan function (5) . Indeed, there has been an explosion of research in this area. As a result, this review cannot provide comprehensive coverage of the field but rather offers an overview of select advances that illustrate the unique contributions and exciting opportunities within the field of chemical glycobiology.
The state of the art of chemical glycobiology is focused on key questions: How are glycans made and degraded, what are their biological roles once in place, and how can these roles be exploited? To address these questions, researchers have employed the complementary strategies of interrogation and perturbation (Figure 1) . The interrogation strategy strives to understand endogenous interactions between natural glycans and their cognate enzymes or binding partners. Access to naturally occurring and novel glycans provides the means to examine protein-glycan or enzyme-glycan interactions. Arrays composed of glycoconjugates 
GLYCAN SYNTHESIS
Defined oligosaccharides and glycoconjugates are critical for unraveling the function of glycans. Obtaining these entities from natural sources is difficult because their production generally involves the participation of multiple transporters and enzymes (6) . This complexity is illustrated by the pathway for eukaryotic glycoprotein synthesis (Figure 2) . The saccharide building blocks (typically nucleotide sugars) must be generated and then transported to the appropriate cellular location, where they can be used by glycosyltransferases. The efficiency of producing any particular glycan depends on the concentration of building blocks, what glycosyltransferases and other biosynthetic enzymes are present, and the K m values of those building blocks for the glycosyltransferases that use them. Pathways for the production of N-glycoproteins, O-glycoproteins, glycolipids, glycosylphosphatidylinositol anchors, proteoglycans, and polysaccharides are influenced by accessibility of the nucleotide donors, but the mechanisms governing the regulation of these pathways are still being elucidated. Thus, it is difficult to obtain sufficient quantities of glycans for study from biological sources.
Chemical strategies are addressing this deficiency by providing the means to generate an ever-increasing diversity of glycans. Naturally occurring glycans can be synthesized, as can derivatives. In this way, critical structureactivity relationships can be elucidated. There are two general approaches for the synthesis of oligosaccharides: chemical and enzymatic. Here, we outline some of the major advances that have occurred on both fronts. More detailed information can be found in several excellent reviews (7) (8) (9) (10) . Schematic depiction of glycoconjugate biosynthesis and cell-surface recognition of glycans. Most exogenously supplied monosaccharides are taken up by cells and converted to monosaccharide donors in the cytosol. The donors are imported into the endoplasmic reticulum (ER) and Golgi compartments, where they are used by glycosyltransferases to assemble glycoconjugates. In the case of N-linked glycoproteins, a core oligosaccharide is assembled in the cytosol, transported into the ER where it is processed by glycosidases, and further elaborated by glycosyltransferases. Once displayed in fully mature forms on the cell surface, the glycoconjugates can serve as ligands for soluble lectins, cell-surface glycan-binding proteins, or glycanbinding proteins on other cells or pathogens. In principle, chemical glycobiology can yield molecules that can be used to inhibit or promote any stage of this process.
Chemical Synthesis of Oligosaccharides
The chemical synthesis of oligosaccharides offers tremendous flexibility. It can give rise to diverse glycans, including those available in minute quantities from biological sources or those for which the biosynthetic enzymes are unknown. Moreover, chemical synthesis provides the means to test the importance of different functional groups because nonnatural sugars can be introduced. The power of chemical synthesis is illustrated by the development of potent and effective sulfated saccharides as anticoagulants (11) . These defined compounds were inspired by analysis of the properties of heparin, an anionic glycosaminoglycan (GAG) that has long been used as an anticoagulant. Heparin can bind antithrombin III, thereby producing a complex that blocks blood clotting. Pharmaceutical-grade heparin is typically isolated from porcine intestinal mucosa as a mixture of sulfated polysaccharides. Chemical synthesis was important in verifying that heparin's activity resides in a critical pentasaccharide recognition sequence. These findings indicate that proteins like antithrombin III can recognize specific sulfated oligosaccharide sequences within GAGs. Additionally, they led to development of the defined anticoagulant drug Arixtra ® . The recent contamination of heparin isolated from biological sources, in which the presence of other sulfated polysaccharides led to over 100 deaths, highlights the utility of therapeutics that are based on defined, synthetic glycans (12) .
The chemical synthesis of oligosaccharides appears deceptively simple. It involves the formation of glycosyl bonds, a reaction first described in 1893 (13) . The approach that was employed then is similar to that used by nature and remains the preferred strategy for chemical synthesis: A donor monosaccharide, equipped with a leaving group at the anomeric position, undergoes reaction with a nucleophilic group on an acceptor (Figure 3a) . In chemical synthesis, a promoter is added to the donor monosaccharide to facilitate the departure of the leaving group.
GAG: glycosaminoglycan
The simplicity of this approach belies its complexity. Glycosylation reactions are regulated by the reactivity-selectivity principle of organic chemistry. The anomeric group must be sufficiently prone to leaving, such that a relatively poor nucleophile like a hydroxyl group can engage in bond formation; however, the donor must not be so reactive that bond formation occurs without stereocontrol. Thus, whether the reaction occurs via an S N 2-like (inversion) or S N 1-like (oxocarbenium intermediate) pathway has a critical influence on the stereochemical outcome. For this reason, the dual problems of regiochemical control and stereoselectivity of glycosylation reactions are intertwined. Fraser-Reid and coworkers' classification of donors as "armed" (fast reacting) or "disarmed" (slow reacting) has led to major advances in the field (14) because it offers insight into how the electronics of the glycosyl donor can be manipulated to control glycosylation reaction outcomes. The reactivity of the donor can be tuned by modifying several factors, including the electron-withdrawing ability of the protecting groups, the lability of the anomeric leaving group, the method of leaving group activation, the conformation of the donor or acceptor, and the nature of the solvent. These changes in reactivity impact glycosylation reaction stereochemistry because they influence the reaction mechanism (S N 2-like versus S N 1-like) (Figure 3a) . It is possible to tune a series of glycosylation reactions to gain outstanding stereoselectivity.
A longstanding yet clever means to achieving stereocontrol is to exploit protecting groups that can influence glycosylation stereochemistry via neighboring group participation (Figure 3b ). In the paradigmatic example, a 2-acyl group forms an acetoxonium ion by attack onto the anomeric carbon. With a protected glucose derivative, the 1,2-acetoxonium ion blocks nucleophilic attack of the acceptor from the α-face and results in the formation of β-glucosides; for mannose, the β-face is blocked, and α-mannosides are produced. This strategy has been used extensively to generate β-glucosides, β-galactosides, α-mannosides, and α-rhamnosides. More recently, novel variations on the neighboring group participation strategy have been employed to access a wider array of glycosidic linkages, including α-glucosides and α-galactosides (7 group participation strategies. Important examples include β-mannosides, β-rhamnosides, and sialic acid derivatives. New insight into the interplay of stereoelectronic and conformational effects is providing strategies to assemble these kinds of linkages (15) . The synthesis of sialic acid derivatives has been especially challenging because the anomeric position is more hindered and possesses an electronwithdrawing group, but the use of protecting groups to alter thiosialoside conformation in combination with novel conditions for donor activation has led to dramatic improvements in glycosylation yields (16) (17) (18) . The value of these new approaches is illustrated by the synthesis of an α2,9-trisialic acid oligomer in a single reaction vessel (one-pot) (19) .
Efforts to streamline the chemical synthesis of oligosaccharides have focused on minimizing purification steps. One approach is to conduct the kind of one-pot glycosylation reactions described above, in which multiple glycosidic bonds are made without isolation or purification of intermediates (Figure 3c ). There are three general strategies to achieve this end. First, the relative reactivities of the glycosyl donors can be varied by protecting group selection, such that the addition of a promoter triggers the most armed glycosyl donor first, and the most disarmed donor eventually engages in the final glycosylation reaction. Second, glycosyl donors can be preactivated before exposure to a glycosyl acceptor, and the order and timing of their addition determine the reaction outcome. Third, orthogonal anomeric leaving groups can be selected that are activated by different promoters. Impressive one-pot syntheses of biologically relevant In its most versatile form, the chemical synthesis of oligosaccharides depends upon glycosylation reactions that involve activation of a glycosyl donor. (a) Treatment with a promoter facilitates the departure of the anomeric leaving group (LG) such that a glycosidic bond can be formed in a substitution reaction with a nucleophilic glycosyl acceptor. Depending on the electron-withdrawing potential of the protecting groups (P) on the glycosyl donor, the reaction can proceed through an S N 2-like mechanism (P = Ac, acetate) or an S N 1-like mechanism in which the stereochemical outcome is controlled by the anomeric effect (P = Bn, benzyl). (b) Neighboring group participation can dictate product stereochemistry. One-pot methods (c) and solid-phase synthesis (d ) are approaches that eliminate purification steps and thereby facilitate glycan assembly. Abbreviation: ROH, an alcohol, including a hydroxyl group of a protected sugar derivative. oligosaccharides are becoming more common. Two notable examples include generation of the branched hexasaccharides GM1 and the tumor-associated carbohydrate antigen Globo-H (20) . In the former, three components were joined in a single reaction; while in the latter, four building blocks were linked (21) .
Another strategy for oligosaccharide synthesis that circumvents the need for multiple purification steps is solid-supported synthesis (22) . In this manifold, reactions can be driven to completion by the addition of an excess of one partner. In the typical configuration, a nucleophilic acceptor substrate is appended onto a solid support and exposed to an excess of activated donor in solution (Figure 3d ). Subsequent steps involve hydroxyl protecting group removal followed by glycosylation. The multiple sites of reactivity and branching found in oligosaccharides require monomers that possess orthogonal protecting groups, which can be masked and unmasked at appropriate stages of glycan construction. Thus, the solid-supported synthesis of oligosaccharides is complicated by the need for diverse building blocks. Nevertheless, the potential of solid-supported synthesis has continued to spark advances, including methods to automate the process. Automated synthesis now can be used to prepare even complex oligosaccharides (22) , such as a branched β-glucan dodecasaccharide; blood group oligosaccharides Lewis x, Lewis y, and the Lewis x-Lewis y nonasaccharide; and tumor-associated carbohydrate antigens Gb-3 and Globo-H. These latter examples are compounds with multiple types of glycoside linkages, and their successful synthesis demonstrates that glycosylation reactions in solid-supported synthesis can occur with excellent stereoselectivity.
There has yet to emerge a universal strategy to form glycosidic bonds with the requisite regio-and stereocontrol. Suitable reaction conditions must be optimized for each glycosidic variation. Thus, current methods are focused on developing sets of standard building blocks that can be used to generate key bioactive oligosaccharides. To this end, many of the targets assembled to date possess linkages that can be formed reliably, such as α-mannosides, β-galactosides, and β-glucosides. It is estimated that approximately 500 orthogonally protected monosaccharides would be needed to synthesize the bioactive oligosaccharides found in mammals (23) , although a recent analysis suggests that 36 building blocks could generate 75% of the known mammalian oligosaccharides (24) . The need for glycans that reflect the diversity of physiological systems is driving efforts to develop methods to prepare all the relevant glycosidic bonds, including those that have been challenging (e.g., β-mannosides, sialic acid derivatives). Progress on this front has made accessible biologically important glycans, such as sulfated GAG sequences and protein glycosylphosphatidylinositol anchors. Despite the rapid development in generating mammalian oligosaccharides, there has been less emphasis on assembling glycans found in microbes. Many of these contain noncanonical sugars (e.g., deoxysugars and furanoses) that pose unique challenges. Methods to assemble these glycans are needed to elucidate their roles in microbes, to probe host-pathogen interactions, and to investigate novel antimicrobial strategies.
Engineering Enzymes for Glycan Synthesis
Enzymatic and chemoenzymatic methods for glycan assembly complement those from chemical synthesis. These approaches harness the components used by physiological systems to generate glycans. Specifically, glycosyltransferases transfer nucleotide-sugar donors onto glycone or aglycone acceptors. The use of these enzymes can facilitate the chemoenzymatic synthesis of glycans, and recent advances have increased the utility of this approach. Historically, nucleotide-sugar donors can only be generated with naturally occurring sugars, although efforts in enzyme engineering indicate that this problem can be overcome (25) . Indeed, the utility of enzymes for generating oligosaccharides has increased in the last decade (26, 27) , owing, in part, to the ability to identify glycosyltransferases from sequence data.
Bacterial glycosyltransferases and related biosynthetic enzymes have proved especially useful for glycan assembly. These enzymes and their variants can be produced and purified more readily than their eukaryotic counterparts, and they often act on a broad array of substrates. In a powerful example, Chen and coworkers (28) used three classes of bacterial sugar-processing enzymes (a sialic acid aldolase, a cytidine 5 -monophosphate-sialic acid synthetase, and a sialyltransferase) to produce a library of 72 biotinylated sialosides in an array format. By screening this array, detailed information about the binding preferences of a key immunomodulatory protein, human CD22, could be gleaned. Another example in which the broad substrate specificity of bacterial glycosyltransferases was exploited is in the production of 70 glycoforms of the natural products calicheamicin and vancomycin (29) . Because glycosylation can influence natural product biological activity, specificity, and pharmacology, the ability to introduce different saccharide substituents is valuable. The enzymes can be engineered to increase their substrate tolerance even further (30) .
Another chemoenzymatic approach to oligosaccharides is based upon glycosidases. Nature's antipode to the glycosyltransferase is the glycosidase, an enzyme that catalyzes the hydrolytic cleavage of glycosidic bonds. Replacement of the active-site water nucleophile with a glycosyl acceptor can result in transglycosylation (26, 27) . Because glycosidases can readily be produced, often are highly soluble and stable, and tend to be more promiscuous than glycosyltransferases, they are attractive as catalysts. Unfortunately, glycosidase-catalyzed transglycosylation reactions suffer from low yields and product hydrolysis because the products are themselves substrates. A major breakthrough in the field occurred with the invention of nonhydrolyzing glycosidases, or glycosynthases.
Glycosynthases were developed by exploiting key features of glycosidase mechanisms.
Glycosynthase: engineered glycosidase capable of catalyzing transglycosylation reactions Glycosidases come in two varieties, retaining and inverting (26, 27) . In general, both possess active sites in which catalytic carboxylic acid residues are proximal (Figure 4) . Most glycosynthases are based on retaining glycosidases, which use a two-step, double-substitution mechanism that proceeds through a covalent carbohydrate-protein adduct (Figure 4b) . Substitution of the nucleophilic active site aspartate or glutamate with a small hydrophobic residue (i.e., alanine) (Figure 4c ) renders the enzyme incapable of hydrolysis. These variants can catalyze the formation of glycosidic bonds between an acceptor and an α-glycosyl fluoride donor. In the engineered enzyme, the product is no longer susceptible to hydrolysis; therefore, transglycosylation reactions can occur in high yields and with high levels of regio-and stereoselectivity.
Glycosynthases engineered to process alternative substrates can be generated by either rational mutagenesis or directed evolution. Because libraries of enzyme variants can be readily prepared, the major roadblock in the discovery of novel glycosynthase enzymes has been the development of high-throughput screens. The enzyme-catalyzed glycosylation reactions are not accompanied by the release of a chromophore, so novel screens were needed. The approaches that have been devised fall into three categories: a yeast three-hybrid chemical complementation assay (31) , an assay based on pH changes (32) , and a fluorescence-activating cell sorting (FACS) assay (33) . In all three approaches, glycosynthase activity is evaluated in whole cells; therefore, protein isolation is not required.
Glycosynthases have been identified (26, 27 ) that act on a range of nucleophiles, including glycone and aglycone acceptors. A notable feature of glycosynthases is that they can produce oligosaccharides that are difficult to obtain using chemical synthesis (e.g., β-mannosides) (34) . In addition, disaccharide fluoride donors and acceptors can be used in transglycosylation reactions, thereby enabling the rapid assembly of complex oligosaccharides (26) . Glycosynthases also can be used to generate oligosaccharides that contain β-glucuronic acid or β-galacturonic acid residues, suggesting they can be used for GAG assembly (26) . Notably, retaining endoglycosidases have also been devised that catalyze the convergent assembly of N-glycans. Specifically, these modified enzymes promote the reaction of oxazolines derived from 2-deoxy N-acetyl glucosamine-containing substrates with asparagine-containing peptides (35) . To complement the linkages that can be formed by engineered retaining glycosidases, inverting glycosidases have been generated that afford α-linkages (36, 37) . Thus, advances in the identification and engineering of both glycosyltransferases and glycosynthases are extending the range of accessible glycans.
Glycoprotein and Glycopeptide Synthesis
In parallel with the development of new methods for oligosaccharide assembly, there have emerged new approaches for glycoconjugate synthesis. The prevalence of glycosylated proteins and the benefits of access to single-protein glycoforms have inspired the development of methods to generate N-and O-glycosylated peptides and proteins. Protein glycosylation can influence the pharmacological properties of therapeutic proteins, including their serum half-lives, their ability to target specific cells or organs, and their modes of clearance. Glycosylation can also exert an influence by playing a direct role in recognition, such that whole glycosylated protein is more than the sum of the parts. A notable example of the latter involves P-selectin, a protein involved in the inflammatory response, which binds to a highly O-glycosylated protein (a mucin) bearing the tetrasaccharide sialyl Lewis x. The tightest complexes between P-selectin and its ligand are formed when specific tyrosine residues adjacent to a sialyl Lewis x motif are sulfated (38) . Thus, the identity of the glycoconjugate as a whole is important for recognition (39) . Together, the mode of P-selectin recognition and the requirement for therapeutic glycoproteins with optimized properties underscore the need to obtain defined glycoconjugates.
Several strategies have emerged that yield defined glycoproteins and glycopeptides. One approach is to employ engineered cell lines or recombinant enzymes to obtain glycoproteins. For instance, complete heterogeneous glycoproteins can be expressed, isolated, and trimmed via glycosidases to bear individual monosaccharide moieties (40) . These monosaccharides serve as starting points for embellishment by recombinant glycosyltransferases or by transglycosylation using endoglycosidases. The latter strategy is especially useful for the rapid assembly of complex glycoproteins because a large glycan motif can be added in a single step (as described above).
Synthetic chemists also have taken on the challenge of glycopeptide and glycoprotein preparation. In focusing on various complex glycopeptides and glycoproteins as targets for synthesis, the Danishefsky research group (41) has pushed the limits of existing synthetic methods. In pursuing their complex targets, including prostate-specific antigen, gp120 fragments, and erythropoietin, they have developed new strategies for the assembly of multiple peptide precursors.
The chemical synthesis of glycoproteins is fueled both by methods to construct complex glycopeptide fragments and the advent of chemoselective ligation reactions to join them. Solid-phase peptide synthesis is generally limited to glycopeptides <50 residues. Chemical ligation reactions, such as native chemical ligation (NCL), alleviate this limitation because they can be used to link peptide fragments together (Figure 5a ) (42) . The NCL process involves the transthioesterification reaction of a C-terminal thioester with an N-terminal cysteine residue of a second peptide. The resulting thioester intermediate subsequently undergoes an intramolecular transacylation reaction to produce a stable peptide bond. One valuable variation on NCL is expressed protein ligation (EPL), in which the peptide component bearing the C-terminal thioester is produced using recombinant DNA methods (43) . Although both NCL and EPL increase the scope of glycopeptide synthesis, they require a cysteine residue, a relatively rare amino acid, at the ligation junction.
The Staudinger ligation of peptide thioesters circumvents the need for cysteine at the junction, as the two peptides couple when a C-terminal phosphinothioester undergoes reaction with an N-terminal azide. The utility of the Staudinger ligation for glycopeptide synthesis is under investigation (44) . Other approaches have been described that capitalize on removable or transient auxiliaries (45) (46) (47) . One of these, sugar-assisted ligation is particularly useful in the construction of N-linked glycans (Figure 5b) (48) . Thus, the means to construct larger glycopeptides and glycoproteins are available and can be used to examine the influence of glycosylation on protein function.
Chemical Glycobiology of Glycolipids
Glycolipids have been implicated in many critical processes, but identifying their precise physiological roles has been difficult. Recent discoveries have revealed that glycolipids can serve as critical immunomodulators. Natural killer T (NKT) cells are a class of T cells that play a central role regulating the immune response, and NKT cells can recognize glycolipids displayed by CD1d-positive antigen-presenting cells. Both endogenous and exogenous glycolipids can serve as CD1d ligands and thereby activate NKT cells. An endogenous glycolipid is presumably necessary for positive selection of NKT cells in the thymus, and NKT cells can recognize exogenous lipopolysaccharides from bacterial pathogens (49) . The synthetic glycolipid antigen KRN7000 (Figure 6 ) and related compounds are illuminating the critical features of the glycolipid that result in NKT cell activation. This understanding can lead to the development of new immunomodulators. Additionally, because glycolipid trafficking and degradation are involved in several diseases, glycolipid analogs serve as probes and therapeutic leads (50) .
Chemoselective Reactions to Modify Glycans
Glycoconjugates are critical tools in the examination of glycan function. They can be immobilized for affinity isolation of glycanbinding proteins, used to generate glycan arrays, or converted to natural or nonnatural probes. Such probes can be generated from The structure of glycolipid antigen KRN7000, which functions as an immunomodulator that leads to natural killer T cell activation. chemoselective reactions (i.e., reactions that occur among select functional groups in the presence of others) of natural and synthetic oligosaccharides (51) . One of the most common strategies is to use the intrinsic reactivity of oligosaccharides, which contain an electrophile at the reducing end, most commonly, an aldehyde. This masked carbonyl group is susceptible to nucleophilic addition, which has been exploited for conjugate production. Nucleophiles, such as alkoxylamine, hydrazine, or acylhydrazine derivatives, can be employed to afford glycoconjugates containing oxime, hydrazone, or hydrazide linkages, respectively (Figure 7a) . These functional groups vary in their stability and in whether the reducing-end sugar exists in the open or closed form. Thus, the mode of conjugation can be chosen for a specific purpose.
An alternative strategy is to generate a glycan that bears a linker that possess a functional group that can undergo reaction with a coupling partner in the presence of hydroxyl, acetamide, carboxylate, and other common carbohydrate functional groups. Perhaps the most commonly used linker, and that used by the Consortium for Functional Glycomics (CFG, http://www.functionalglycomics.org), is an aminopropyl group appended to the anomeric position. The resulting amine-bearing oligosaccharides can undergo reaction with several types of partners, including those bearing N-hydroxysuccinimidyl esters, aldehydes (followed by reductive amination), or dimethyl squarate (Figure 7b ) (52) (53) (54) (55) . Other chemoselective linkage strategies rely on the unique reactivity of thiol-containing saccharides, which can undergo conjugate addition to maleimide-bearing glycans (56, 57) or form disulfide-linked conjugates (58) . Cycloaddition reactions, including Cu(I)-catalyzed azidealkyne (Figure 7c ) and Diels-Alder reactions (Figure 7d ), also have been used (59, 60) . Although olefin metathesis depends upon a metal carbene catalyst, remarkably, it has been shown to be compatible with carbohydrate functionality (Figure 7e) , including sulfate groups (22, 61) . The Staudinger ligation reactions of azides with phosphinoesters or phosphinothioesters also are useful chemoselective reactions, and the phosphinoester version has been used in diverse contexts (Figure 7c ) (62, 63) . Some examples of how the different aforementioned chemoselective reaction processes have been exploited to investigate glycan function are described in subsequent sections.
INTERROGATION OF GLYCAN RECOGNITION
Glycans are present both inside and outside of cells. Within cells, glycosylation is critical for protein trafficking, and more recently, it has been found to influence gene expression (64) . Glycans on the surface of pathogens can serve both as a protective shield and as a means for recognizing and entering target cells. Similarly, protein-glycoconjugate interactions are a major line of communication between cells and their environment. Lectins, proteins of nonimmune origin that bind to specific glycan structural motifs, typically use solvent-exposed binding sites to interact with their target oligosaccharide ligands (65) . As a result, they bind weakly to single carbohydrate residues and even oligosaccharides. Indeed, monovalent protein-glycan binding dissociation constants are often in the range of 10 −4 to 10 −3 M (66). These low affinities might suggest that protein-glycan complexes are not important, yet weak binding is ideal for mediating cell adhesion. When cells interact, glycans on one cell surface can bind to multiple copies of a lectin on another, thereby increasing the apparent binding constant (functional affinity). The advantage of using low-affinity interactions for cell-cell recognition is that, when each individual receptor-ligand interaction is weak, binding will be kinetically labile. In this way, only cells with the correct combination of receptor-ligand pairs will interact stably.
The involvement of multivalent binding in many protein-glycan interactions complicates the identification of the relevant endogenous ligands. Standard receptor-ligand assays lack the necessary sensitivity to monitor low-affinity binding. Accordingly, many methods to assess protein-glycan interactions depend upon multivalent display of one or both binding partners. Such assays have higher sensitivity and can have even higher specificity (67, 68) . Moreover, they can minimize the amount of material required, which is especially important considering the challenges associated with the acquisition of glycans. Still, they are best used to compare compounds because determining the true equilibrium constant for a multivalent interaction is complicated. Indeed, many distinct types of binding modes can contribute to the strength of a multivalent interaction (69, 70) . Glycan arrays are a technology that invokes multivalent binding and allows many different samples to be compared simultaneously. New tools for array fabrication and analysis have been advanced that depend on a combination of analytical, biochemical, and synthetic methods. The topic of glycan arrays has been reviewed extensively (71) (72) (73) (74) (75) , and our goal is to highlight relevant contributions of chemistry to their development.
Glycan Arrays
Glycan arrays have been widely embraced as platforms suited to rapid screening of protein binding to carbohydrates. On the basis of principles developed for DNA and protein microarrays, glycan arrays have emerged as tools to assess the specificities of lectins, antibodies, and other glycan-binding proteins. There are many methods for fabricating glycan arrays, yet all have the same overall features. Specifically, natural or synthetic glycans are immobilized onto a surface through either covalent or noncovalent attachment. The resulting glycan surfaces are treated with whole cells, complex biological samples such as sera, or isolated glycan-binding proteins. Binding can be assessed using fluorescence or another type of reporter.
The first challenge to creating glycan arrays was to develop a method to spatially pattern various oligosaccharides or glycoconjugates on a surface. To date, the methods implemented for array fabrication fall into three general categories: (a) immobilization by physical adsorption, (b) immobilization via high-affinity, specific noncovalent interactions, or (c) covalent capture, in which complementary reactants are displayed on the glycan and the surface. Physical adsorption, which exploits the ability of glycosylated proteins or glycolipids to adhere to the surface, helped to establish the utility of glycan arrays as a multivalent assay platform (76) (77) (78) . Nonnatural glycolipids can be generated from oligosaccharides that possess a free reducing end (i.e., a masked aldehyde) using lipids that bear nucleophiles, such as amines (79) or alkoxylamines (80) . In an innovative variation of the adsorption approach, fluorous lipid tags, which can be used both for synthesis and immobilization, have been employed (81) . An alternative approach is to immobilize a glycoconjugate through specific noncovalent complexes, such as biotin-streptavidin binding or DNA hybridization (82) . In general, however, in most arrays, the glycan is linked to the surface by covalent bond formation.
A common means for glycan array construction is to exploit the unique reactivity of the anomeric position. For example, oligosaccharides can be appended to a surface that presents nucleophiles via reaction with the reducing end (83) . Similarly, the reducing end can undergo reductive amination with 2-aminobenzamine derivatives in solution (84, 85) , and these fluorescent saccharides can be subsequently attached to the surface. In the latter approach, the fluorescent tag serves multiple purposes: It provides a means to purify heterogeneous pools of natural glycans, it can react with an electrophilic (e.g., succinimidyl ester-or epoxidefunctionalized) surface, and it provides a means of quantifying the immobilization efficiency. Reductive amination reactions of oligosaccharides with the lysine side chains of proteins also have been exploited to yield multivalent glycoconjugates that were subsequently immobilized; the presentation of these conjugates on the surface can mimic that of glycosylated proteins (86) (87) (88) .
When glycans are generated by chemical synthesis, tailored functional groups for immobilization can be introduced. As mentioned previously, the mostly widely used strategy is to introduce a linker bearing an amine group and exploit its nucleophilicity with N-hydroxysuccinimidyl ester-coated slides. A complementary approach is to build oligosaccharides directly onto the array surface (56) . This general strategy provides not only a means to construct known glycan structures, but also the opportunity to interrogate the selectivities of glycosyltransferases (89) .
Many relevant protein-glycan interactions can be uncovered using glycan arrays as experiments focused on Tn antigen illustrate. The Tn antigen is rarely expressed in normal tissues but is associated with several cancers. Glycan arrays were used to reveal that only a subset of prostate tumors display the Tn antigen, a finding that may have therapeutic implications (90) . Another instructive feature of the Tn antigen studies is that variations in the specificities determined by individual research groups were different. This unexpected outcome highlights the variability that can arise from glycan array data and the need for standardization.
Despite the challenges, glycan arrays are providing new insight into the protein-binding specificities in complex systems, including those involving highly anionic sulfated GAG sequences. GAGs such as heparin, heparan sulfate, and chondroitin sulfate are involved in processes ranging from development, angiogenesis, cancer metastasis, wound healing, and viral invasion (91) . GAGs can be composed of heterogeneous sequences, but the idea that specific sequences are recognized selectively has been controversial owing to a paucity of supporting data. To investigate this hypothesis,
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GAG arrays have been assembled from the attachment of di-to hexasaccharides bearing amine-and aminooxy-terminated linkers to electrophilic surfaces (52, 53, 92) . The resulting arrays are bolstering the hypothesis that specific GAG sequences have defined physiological functions (93) (94) (95) .
With all the advances in array fabrication, the most significant barrier to the widespread adoption of glycan arrays is the limited availability of oligosaccharide structures. The CFG provides arrays for the nonspecialist that focus on human and mammalian glycans. The version currently available to researchers (Version 4.0) displays 442 mammalian glycans, whereas the pathogen array presents 96 glycans derived from seven pathogen species. Researchers need to continue to identify and generate a broad array of glycans to extend further the utility of the array platform. Additionally, although the array surface is suited to multivalent interactions, it is unclear how the mode of glycan display influences protein recognition. New technologies to address the role of presentation include the immobilization of multivalent glycosylated scaffolds, such as proteins and peptides (87, 88) or polymer ligands (86) . Additionally, fluidic arrays have been introduced that are designed to mimic the mobility of glycoconjugates imbedded in a lipid bilayer (96) . As glycan array technology continues to evolve, standard methods, from fabrication to interpretation, will undoubtedly emerge.
Lectin Arrays
Lectin arrays provide a means to assess lectin binding to individual glycoconjugates, patterns of cell-surface glycosylation, and pathogenlectin interactions (73) . They can provide important structural information about uncharacterized glycans and serve as multivalent and sensitive monitors of protein-glycan interactions. Lectin arrays are typically fabricated using commercially available carbohydratebinding proteins of defined specificity. Mahal and coworkers (97) have pioneered a two-color technique for the analysis of glycans from mixtures, similar to that employed for DNA arrays. The ratiometric data obtained from a pair of dye-swapped arrays afford reproducible data. This method was used to support the hypothesis that the human immunodeficiency virus (HIV) co-opts the microvesicular exocytic mechanism to exit T cells. Lectin array technology also has been used to elucidate differences in sialic acid expression between nontumorigenic and adenocarcinoma cells (98) .
Although lectin array technology is more nascent than that of glycan arrays, some of the challenges are shared. Notably, just as glycan arrays are limited by the availability of oligosaccharides, lectin arrays are restricted by the recognition specificities of known lectins. Most commercially available lectins are isolated from plants, but pathogenic organisms often contain unique glycan structures that are not recognized by the available and characterized lectins. As more carbohydrate-binding proteins become available, the value of these arrays and their ability to distinguish between different cell types will increase.
Generally, glycan and lectin arrays use fluorescence to detect protein-glycan interactions. Methods of introducing probes include conjugation of fluorescent tags to cells or lectins, cell staining, and incubation with labeled antibodies. Modification-free techniques for array analysis are also under development, and these include evanescent-field fluorescence detection (99, 100), surface plasmon resonance (101), and fluorescence interference contrast microscopy (102).
PERTURBATION OF GLYCAN FUNCTION
A traditional approach to perturb protein function is to delete a protein or proteins of interest within a cell or organism. The application of RNA interference or gene knockouts can provide insight into the importance of a lectin or an enzyme involved in glycan biosynthesis (103) . Drawing conclusions from single gene deletions of enzymes involved in the biosynthesis or processing of glycans, however, can be difficult, as studies of CD22 illustrate. Mice that lack CD22 are hypersensitive to B cell antigen receptor stimulation, but those that lack the glycosyltransferase (ST6Gal-I) that generates the CD22 ligand have compromised B cell responses to antigen (104) . To determine that CD22-ligand interactions suppress B cell activation required further experimentation. Another complication of genetic experiments is the masking of phenotypic changes because of compensation by other enzymes, which can camouflage the function of the protein of interest. Alternatively, a single protein may have multiple roles, but a null mutant lacks all of them. Perhaps most significantly, genetic methods were devised to examine protein function; even though they can be applied to a particular protein that binds or generates a glycan, they do not report on the function of the glycan itself. Thus, although genetic methods are powerful, complementary strategies are needed. One alternative is to perturb glycan function with compounds that disrupt or alter specific protein-glycan interactions or the production of specific glycans. Such perturbations can shed light on the physiological processes mediated by a glycan and also provide therapeutic leads. In the following sections, we outline recent advances in the use of synthetic molecules to probe glycan function.
Perturbation of Protein-Glycan Recognition with Monovalent Ligands
The recognition that protein-glycan complexes are critical in physiological and therapeutically important processes, which include inflammation, immune system function, cancer, and host-pathogen interactions, has fueled efforts to generate inhibitors. The aforementioned features of the proteins that bind glycanstheir low-affinity and solvent-exposed binding sites-render the generation of effective ligands a formidable challenge. Still, inhibitors with the requisite attributes are emerging from an enhanced understanding of glycan-lectin interactions coupled with advances in highthroughput methods for identifying them. Oligosaccharides based on endogenous glycans are an obvious starting point (105) , but converting these polar molecules into potent inhibitors has been difficult. The aim is to devise molecules with improved affinity and selectivity, reduced polarity, and greater stability than naturally occurring glycans. One strategy to address these issues is to apply molecular design principles. Although the rationale used to optimize a glycomimetic generally is tailored to the specific lectin target, analysis of the successful design efforts to date reveals some common strategies (105) . First, either structurefunction relationship data or the structure of the complex is used to identify glycan functional groups that are critical for binding. Second, nonessential polar functional groups (e.g., hydroxyl and acetamido groups) are removed to increase lipophilicity. Third, conformational control elements are introduced to preorganize the oligosaccharide to adopt the active, bound conformation. Fourth, the observation that many glycan-binding sites are lined with aromatic residues can be exploited by introducing aromatic substituents at key positions to enhance binding affinity. Some examples that illustrate successful implementation of these design elements follow.
The development of galectin inhibitors highlights the value of the aforementioned strategies. Galectins are a class of glycanbinding proteins found in multicellular organisms; humans possess 12 genes encoding galectin family members (106) . Their name comes from their propensity to bind β-galactose-containing oligosaccharides, although individual galectins can exhibit distinct selectivities. These proteins are involved in a range of physiological processes, including regulation of cell growth, differentiation and apoptosis, cell adhesion, chemoattraction, and cell migration (107, 108) . They also are implicated in the inflammatory response and tumor progression. Unlike most mammalian lectins, galectins are not membrane bound but rather are produced in the cytosol and then secreted. Consistent with their ability to occupy two different cellular locations, galectins appear to have important intracellular and extracellular functions. Still, their functional roles have been difficult to discern, and the relevance of glycan binding is not always clear. Thus, inhibitors that could interact selectively with different members of the galectin family could serve as valuable biological probes.
Several of the galectins, including galectin-3, form complexes in which the 4-and 6-hydroxyl groups of galactose form hydrogen bonds to the protein, whereas the remaining hydroxyl groups do not make direct contact (109) . These nonessential ligand hydroxyl groups serve as points for modification, and it was postulated that aromatic substituents at the 3-position would enhance binding. Inhibitors of this type possess dissociation constants that are 1000-fold more potent (K d < 50 nM) than N-acetyllactosamine (110) . They also show selectivity (∼100-fold) for galectin-3 over other galectins. A galectin-3 ligand of this type revealed that glycan binding by this lectin plays a role in alternative macrophage activation (111) . Alternative macrophage activation is linked to processes ranging from asthma to wound repair and fibrosis; therefore, these studies suggest that galectin inhibitors could have beneficial therapeutic effects. Many efforts to devise glycomimetic inhibitors have focused on the C-type lectin family, whose members require Ca 2+ for binding. Three lectins from this group, E-, L-, and Pselectin, have served as a major testing ground for glycomimetic design. The selectins have been targets because of their participation in recruiting leukocytes to inflamed tissue and their putative roles in tumor cell migration. Each selectin can bind to the structurally related tetrasaccharides sialyl Lewis x and sialyl Lewis a, and extensive structure-activity studies with oligosaccharide derivatives established the key features that contribute to binding. For E-selectin complexation, critical attributes include the carboxylic acid group, the three hydroxyl groups of fucose, and the 4-and 6-hydroxyl groups of galactose. This motif was used to guide the design of a glycomimetic, in which the relevant groups were presented on a scaffold that is preorganized for binding (Figure 8b) (105) . Ligands with even less resemblance to the saccharide residues they were designed to mimic also were effective. For example, peptide motifs appended to fucose bind to P-selectin. These also exhibit selectivity for P-over E-selectin, which is consistent with the ability of the former to recognize an epitope encompassing a carbohydrate and a peptide backbone (Figure 8c) (112) . As other examples of noncarbohydrate ligands, two small-molecule inhibitors of P-selectin were generated from a quinoline salicylic acid scaffold (Figure 8d ). These compounds have progressed into clinical trials for rheumatoid arthritis and atherothrombotic vascular events (113) .
To date, most glycomimetic design strategies have focused on individual proteinsaccharide complexes. In contrast, peptidomimetics often model structural elements (e.g., a β-turn) known to be critical for proteinprotein contacts. There are common features of the C-type lectin complexes that might be exploited in inhibitor design. Many C-type lectin complexes use adjacent hydroxyl groups on fucose to coordinate the protein-bound calcium ion, which suggests that scaffolds that possess key Ca 2+ -coordinating groups can be modified to enhance affinity or specificity. One such strategy has been described that employs focused libraries of glycomimetics using shikimic acid as a building block (114) . These have yielded inhibitors of the prototypical lectin mannose-binding protein A. The identification of other approaches that can be applied broadly to other lectin classes could accelerate the pace of glycomimetic generation.
An alternative to the design approach is to identify small-molecule inhibitors of lectins through screening. This strategy could be valuable if cell-permeable ligands could be found; to date, however, a limited number of such compounds have been described. Studies of the selectins have yielded some positive results (105) , as have investigations focused on the Ctype lectin DC-SIGN. DC-SIGN facilitates several host-pathogen interactions, including dissemination of HIV (115) . Inhibitors of DC-SIGN were identified from a 35,000-compound small-molecule library using a highthroughput fluorescence competition assay (116) . Seven compounds were identified that are ≥100-fold more potent than N-acetylmannosamine for DC-SIGN (Figure 8e) . None of the small molecules that bind the selectins or DC-SIGN resembles carbohydrates, an observation that provides impetus to use high-throughput screens to search for effective inhibitors of other carbohydratebinding proteins.
Perturbation of Protein-Glycan Recognition with Multivalent Ligands
An alternative strategy to overcome low-affinity protein-glycan interactions is to employ multivalent ligands. This approach can be especially effective for blocking protein-glycan engagement at the cell surface. Naturally occurring, multivalent glycan displays are widespread; representatives include glycosylated proteins, the glycan coats of bacteria, viruses, other pathogens, and the surfaces of mammalian cells. Many carbohydrate-binding proteins are oligomeric and therefore are present in multiple copies on the cell surface. In this way, both cell-surface glycans and lectins are poised to engage in multivalent binding.
Multivalent carbohydrate derivatives can exploit unique modes of recognition not available to their monovalent counterparts. Many lectins contain more than one saccharide-binding site or can oligomerize to form larger structures with multiple binding sites. Multivalent ligands that can span the distance between binding sites have an advantage over their monovalent counterparts. This chelation mechanism is advantageous because the translational entropy cost is paid with the first receptor-ligand contact (70, 117) . Nevertheless, the apparent affinity of a multivalent interaction often is less than might be expected, presumably because of the conformational entropy restrictions incurred by multipoint binding. Multivalent ligands also can exhibit functional affinity enhancements by occupying secondary binding sites. Alternatively, glycan-binding proteins may cluster in a membrane microdomain either in response to a multivalent ligand or in response to cellular signals. Although multivalent ligands can be potent inhibitors, their ability to cluster glycanbinding receptors allows them also to serve as activators of signaling pathways (69) . Thus, depending on their binding modes, multivalent ligands can exhibit a wide range of different activities.
Chemical synthesis can provide architecturally diverse multivalent ligands, including low-molecular-weight displays, dendrimers, polymers, liposomes, and proteins (69, 118) . This diversity can be used to optimize a synthetic ligand for a given application. For example, unlike naturally occurring, multivalent glycan ligands, the valency of a synthetic ligand can be altered systematically by varying the length or size of the scaffold. Polymers of defined lengths or dendrimers of different generations will possess different valencies and therefore differing activities. Evaluating the impact of these changes on the biological response can illuminate the mechanisms underlying the function of natural protein-glycan interactions and lead to highly efficacious inhibitors.
Potent multivalent inhibitors for several medically relevant protein-glycan interactions have been identified. One target that has been explored is influenza virus hemagglutinin, and a number of multivalent sialic acid derivatives have been generated that block the interaction of the virus with cells (119) . Other hostpathogen interactions also can be inhibited with multivalent ligands, and representative examples include compounds that prevent Pseudomonas aeruginosa adhesion or the binding of uropathogenic Escherichia coli (120) . Although the influence of scaffold structure is just beginning to be explored (121) , the inhibitors of the AB 5 bacterial toxin family highlight the benefits of multivalent ligand design. This toxin family is characterized by one active component (A) and a pentamer of subunits (B) that bind carbohydrates displayed on cellular surfaces. The AB 5 toxins are responsible for diseases ranging from travelers' diarrhea (heat-labile enterotoxin), to acute kidney failure in children (Shiga-like toxins), to fatal cholera (Cholera toxin). Efforts from several groups have highlighted the importance of distance between binding motifs (118), a parameter that appears to be at least as important as the identity of the ligands themselves. For example, a pentacyclen core was used to display five galactose residues that were tethered using a range of linker lengths (122) . The activity of the multivalent ligands against heat-labile enterotoxin depended on the linker. The most potent ligand possessed the longest linker and was 10 5 -fold more active than the corresponding monovalent galactose derivative. Dynamic light scattering experiments indicated a 1:1 protein-ligand complex, suggesting the efficacy of the ligand is the result of the chelate effect. In another example, Bundle and coworkers (123) used glucose as a core structure to display two trisaccharides per glucose oxygen on long spacer arms (Figure 9a) . This STARFISH ligand was designed to occupy a Shiga-like toxin through both the primary binding site and a subsite. It was a highly effective inhibitor (IC 50 0.24 nM). Unexpectedly, however, X-ray crystallographic analysis revealed that the designed multivalent ligand did not bind a single pentamer but rather it dimerized two copies by occupying all five B subunits. Thus, for both AB 5 toxin ligands, the spacing between the binding elements was critical for activity, even though their modes of multivalent binding differ.
Most applications of multivalency in glycobiology involve the use of multivalent ligands as inhibitors, but multivalency also can be used to activate particular cellular processes. An example involves blocking the action of L-selectin, which mediates leukocyte migration and recruitment from the blood to lymphatic tissues and sites of inflammation (124) . The natural ligands for L-selectin are mucins that present a multivalent display of sialyl Lewis x derivatives. Experiments using mucin mimics highlight the importance of multivalency for L-selectin recognition (Figure 9b) . In this study, synthetic multivalent ligands were generated using the ring-opening metathesis polymerization (ROMP). This polymerization is especially valuable for multivalent ligand synthesis because the length, and therefore valency of the ligands, can be controlled. Interestingly, the ROMP-derived polymers not only bind L-selectin, but also promote its proteolytic release, or shedding, from the cell surface (125) . These results suggest that clustering L-selectin may signal for its cleavage.
Multivalent displays of oligosaccharides also are being tested as vaccines against bacteria, parasites, and cancers (7, 9, 126, 127) . Although oligosaccharides typically do not elicit robust immune responses, they are effective when appended to an immunogenic carrier protein. To boost immunity further, novel multivalent conjugates are being developed. An innovative example is a conjugate that simultaneously displays multiple groups: a B cell epitope, a T helper epitope, and a toll receptor ligand (128) . These groups can synergistically augment immune responses by recruiting different aspects of the innate and adaptive immune responses.
Multivalent ligands also can be used to recruit lectins to signaling complexes. Such assemblies are useful in controlling cellular responses because some glycan-binding proteins enhance signaling and others diminish it. Although vaccine designs are necessarily focused on augmenting the immune response, compounds that suppress autoimmune responses also are needed. The aforementioned CD22, which dampens immune activation, is a sialic acid-binding lectin from the Siglec family. A CD22 ligand [i.e., N-acetylneuraminic acid-α(2,6)-galactose-β(1,4)-glucose] was attached to a multivalent antigen, such that the resulting polymer engaged both CD22 and the B cell antigen receptor (Figure 9b) (129) . This sialylated antigen inhibited B cell activation. These results identify a mechanism by which antigen glycosylation can suppress immune activation. Moreover, they highlight how multivalent ligands can be used to perturb the assembly of glycan-binding proteins on the cell surface. Selected examples of multivalent ligands that can be used to perturb protein-glycan recognition. (a) The pentameric STARFISH core has been used to devise potent inhibitors of the AB 5 toxin family. (b) Polymers are useful scaffolds for producing multivalent ligands. The structures depicted were generated using the ring-opening metathesis polymerization (ROMP), which differs from most polymerization reactions in that it can afford defined ligands. Abbreviation: Ac, acetate.
A new but related aspect of multivalent protein-glycan interactions involves exploiting noncovalent interactions to create functional supramolecular protein-glycan assemblies. Two different general strategies have emerged; both 
Figure 10
Polymeric ligands possessing a preorganized structure can form supramolecular complexes that display increased functional binding affinity or increased serum half-life.
rely on bifunctional ligands. In the first, polymeric ligands that display multiple copies of two distinct recognition elements, such as the sialylated antigens described above, promote macromolecular protein assemblies. Multivalent assemblies of this type were used to address the disappointing in vivo activity of the aforementioned pentavalent inhibitors of Shiga toxin. Polymeric ligands that possess a preorganized architecture promote the formation of complexes of Shiga toxin 1 and an endogenous circulating pentavalent receptor human serum amyloid P (Figure 10 ) (130) . When tested in mice, a stable macromolecular complex was generated with a prolonged half-life in circulation. Most importantly, the animals were protected from the toxin.
A second approach is to employ compounds that are not polymeric yet possess two different epitopes (54, 131) . A bifunctional ligand was used to selectively kill tumor cells via recruitment of a glycan-binding antibody, which subsequently led to complement activation. The bifunctional ligand was designed such that, upon binding to a cell-surface receptor associated with cancer, it could present the antigenic epitope galactosyl-α(1,3)-galactose (α-Gal), which would allow cells to be recognized as foreign by the naturally occurring anti-α-Gal antibody (54) . The α-Gal epitope is not found in humans (132) , but human serum contains a significant level of anti-α-Gal antibody (about 3% of circulating antibody). Cells displaying α-Gal epitopes are subject to complementmediated cell killing. Importantly, the recruitment of anti-α-Gal to the cell surface requires a multivalent presentation of glycan residues. The final conjugate consists of an α-Gal epitope linked to an integrin α v β 3 -binding ligand, as this integrin is upregulated on tumor cells. When cells are treated with the bifunctional ligand, complement-mediated lysis occurs. Cells with low levels of the integrin receptor were spared, whereas tumor cells displaying high levels of integrin were killed selectively (54) , and this selectivity underscores the advantage of using multivalent interactions for cell targeting. Thus, ligands that promote macromolecular assemblies of carbohydrate binding-proteins can co-opt the function of glycans and their receptors for new purposes.
Perturbation of Glycan Assembly
An emerging strategy to understand glycan function is to block selected steps in glycoconjugate assembly or disassembly. To this end, efforts have been launched to develop inhibitors of specific glycosyltransferases, glycosidases, and other sugar-processing enzymes. Inhibitors can illuminate both the biological roles of glycans and the mechanisms behind their turnover and assembly. Indeed, compounds that selectively target major pathways (including the production of N-glycoproteins and O-glycosylated mucins, as well as the attachment of O-GlcNAc residues) could be used to probe the roles of different glycan classes. Moreover, inhibitors of the production of specific glycans in tumors or pathogens could serve as therapeutic leads.
Nature has provided some design strategies for generating compounds that inhibit Nglycosylation in the form of natural products. For example, tunicamycin (Figure 11a ) blocks a crucial transphosphorylation reaction between UDP-GlcNAc and dolichol-phosphate that generates dolichol-PP-GlcNAc. This step is required for the synthesis of N-glycoproteins, and tunicamycin has therefore been used to illuminate the consequences of deficiencies in Nglycan production (133) . Another strategy to inhibit N-glycosylation is to block the activity of the oligosaccharyltransferase complex, and this mode of inhibition is exhibited by a cyclic peptide that adopts the conformation of the peptide acceptor (134) . Cell-permeable compounds that block N-glycosylation selectively in either bacteria or eukaryotes would be useful probes (135) .
Inhibitors of glycosyltransferases involved in O-glycan biosynthesis also have been sought (136) . Given that O-glycans are involved in processes from pathogen binding to cancer, inhibitors will be useful for investigating the physiological and pathophysiological roles of this important class of glycans. For these targets, there are no obvious starting points because natural product inhibitors have not been identified, and the peptide sequence requirements for glycosylation have not been fully delineated. Thus, high-throughput screens were employed. One innovative assay exploits the observation that the rate of proteolysis of a glycosylated peptide is diminished relative to that of its unmodified counterpart (136) . By appending N-and C-terminal fluorophores that can engage in Förster resonance energy transfer, a peptide's susceptibility to proteolytic cleavage can be assessed. When a glycosyltransferase is present, cleavage is decreased, whereas the presence of a glycosyltransferase inhibitor restores rapid proteolysis. This assay format has 
Figure 11
Natural products (compounds 11a-11c) have inspired the generation of drugs (compounds d and e) that act as transition-state analogs and thereby inhibit influenza virus neuraminidase. Inhibitors of this type can be used to perturb glycan assembly.
UDP-GlcNAc:
been employed to identify compounds that target O-GlcNAc transferase (OGT) (Figure 12) . OGT is an essential enzyme that regulates signaling through its ability to mediate intracellular O-glycosylation. Compounds that block this enzyme can serve as valuable probes that complement those known for the corresponding O-GlcNAc residue hydrolyzing glycosidase. These studies illustrate the value of highthroughput screens to identify inhibitors, and a number of strategies have been implemented including those that rely on glycan arrays (72, 137) , activity assays (138) , and binding assays (139 Compounds identified in a high-throughput screen as inhibitors of the essential glycosyltransferase O-GlcNAc transferase (OGT).
the cleavage of sialic acids on the host cell surface to enable viral infection. The design of these compounds was inspired by natural product glycosidase inhibitors, such as deoxynojirimycin (Figure 11b ) and castanospermine (Figure 11c ). These compounds are amines that are protonated at neutral pH, and they are thought to mimic an oxocarbenium transition state (140) . Design strategies inspired by transition state models have led to valuable drugs; these include zanamivir (marketed as Relenza ® ) (Figure 11d ) and oseltamivir (marketed as Tamiflu ® ) (Figure 11e) for the treatment of influenza (141) . These compounds, which block viral replication and infection of new host cells, underscore the value of targeting enzymes that operate on glycans. Moreover, this strategy has been applied to afford inhibitors of other glycosyltransferases or glycosidases (142) . Carbohydrate-modifying enzymes critical for cell wall biosynthesis in microbes also have been the objects of inhibition studies. Several investigations in this area have employed ligand displacement assays that rely upon fluorescence polarization (FP). FP assays serve as a general method to study enzymes that use nucleotide sugar substrates, which are prevalent yet poorly understood. FP assays have been used to identify inhibitors of two different enzymes essential for cell wall biosynthesis: UDP-galactopyranose mutase (UGM), which is found in mycobacteria and catalyzes the interconversion of the isomeric compounds UDP-galactopyranose and UDP-galactofuranose, and the glycosyltransferase MurG, which is a bacterial glucosaminotransferase involved in the biosynthesis of the crucial bacterial cell wall component peptidoglycan.
In the case of MurG, a fluorescent probe was designed based on the structure of the donor, UDP-GlcNAc, complexed to the enzyme (Figure 13) (139) . A library of 64,000 compounds was screened, and subsequent analysis revealed many of the most potent binders possessed a common scaffold: a 1,3-disubstituted heterocyclic core. Because glycosaminotransferases are present in all organisms, probes or lead compounds must bind the bacterial enzyme selectively. Importantly, the inhibitors are selective over other nucleotidesugar-processing enzymes (143) .
In another example, a UDP-fluorescein probe was used in a 16,000-compound, highthroughput inhibitor screen of the UGM from Mycobacterium tuberculosis (144) . The active compounds identified share structural features with those found to block MurG, including a five-membered thiazolidinone heterocycle, substituents at the 1-and 3-positions, and at least one aromatic group that might mimic the uracil (Figure 13 ). This class of thiazolidinone derivatives is subject to reaction with nucleophiles in a biological milieu (144) , which limits their utility as biological probes or therapeutic leads. Still, their identification in two independent screens suggests that the shape of these compounds is well suited for targeting nucleotide-sugar-utilizing enzymes. Further design and optimization based on this hypothesis resulted in the identification of compounds that block mycobacterial growth (Figure 13) (145) . These studies underscore that high-throughput screens can be used as tools to aid in identifying new therapeutic targets and, more generally, as probes of glycan biosynthesis. Fluorescence polarization (FP) has been used to identify inhibitors for sugar-processing enzymes with essential roles in bacterial cell wall biosynthesis. These enzymes include the glycosyltransferase MurG and the isomerase UDP-galactopyranose mutase (UGM).
Exploiting Alternative Substrates in Glycan Biosynthesis
Modified glycans can be used to investigate glycan recognition, biosynthesis, cellular or organismal localization, and turnover. For example, primer saccharides can be introduced that compete with endogenous substrates for the glycosyltransferases (146) . These compounds serve as decoys by preventing the production of physiological glycoconjugates. This approach can block the generation of specific cellsurface glycoconjugates, but the consequences of harboring the resulting glycan chains within cells have not been elucidated fully. Glycan biosynthetic pathways also can be co-opted to incorporate monosaccharide analogs, thereby generating modified glycoconjugates in cells or organisms. The feasibility of this strategy was demonstrated by exposing cells to N-propanoylmannosamine, an analog of Nacetylmannosamine, a key intermediate in the biosynthesis of sialylated glycans. With this treatment, the cell-surface glycans generated bear sialic acid residues with N-propionamide groups (147) . This general strategy has subsequently been exploited for diverse applications. The incorporation of a modified building block can interfere with subsequent glycosylation reactions, thereby blocking the production of specific glycan structures. In this way, glycan functional roles can be interrogated. For example, when cells are treated with Nbutanoylmannosamine, they display truncated polysialic acid chains and provide a means to assess the influence of the length of polysialic acid on neuronal plasticity (148) . Another example of altering glycan production employs 2-deoxygalactose, which precludes the generation of the fucosyl-α(1,2)-galactose epitope. Investigations using this deoxysugar revealed that fucosylation prevents the proteolytic degradation of synapsin, a critical regulator of neuronal function (149) . The incorporation of modified saccharide residues also has been used to investigate the requirements for glycan recognition. For example, the use of metabolic engineering to generate N-glycosyl-substituted sialylglycoconjugates disrupts the interaction of neural glycoproteins with myelin-associated glycoprotein (150) . N-Acetylmannosamine derivatives also have been used to decorate tumor cell surfaces with immunogenic glycans (151) . Thus, altering glycan biosynthetic pathways can provide insight into the functional roles of specific carbohydrate epitopes.
Oligosaccharide biosynthesis also can be co-opted to introduce unique functional groups into cellular glycans. The Bertozzi group (152) has investigated different aspects of glycobiology using metabolic labeling combined with chemoselective functionalization reactions. In one example, they showed that N-azidoacetylglucosamine (GlcNAz) could be incorporated at sites subject to O-GlcNAc modification. Azides are valuable handles because they are absent from biological systems and are relatively unreactive toward most biological function groups. As stated above, they can undergo transformations in the presence of other nonphysiological function groups. Specifically, an azide-bearing compound can be coupled using a Staudinger ligation reaction with a phosphinoester bearing a reporter (e.g., biotin) to generate a conjugate. This reaction scheme was utilized to profile proteins modified with O-GlcNAc. Cells were treated with GlcNAz to afford azide-substituted glycoproteins that were subsequently modified for isolation and characterization (153, 154) . A similar strategy has been used with Nazidoacetylgalactosamine (GalNAz) to detect mucins. Metabolic labeling also can be used to introduce photoaffinity labels, such that cross-linking to glycan-binding proteins can be carried out. For example, aryl-azide (155) or diazirine (156) moieties can be incorporated into sialic acid-bearing glycans at the C9 or C5 positions of sialic acid, respectively. When these photoactivable groups are displayed on cell-surface glycans, they can be used to identify glycan-binding proteins by covalent trapping. The ability to modify glycans by metabolic incorporation also can be used to introduce groups to alter cell adhesion. The display of N-thioglycolylneuraminic acid in cell-surface glycans causes self-assembly into large clustered cell aggregates, which may prove valuable for tissue engineering purposes (157) .
Illuminating Glycan Biosynthesis
Our understanding of glycans would be advanced by strategies to visualize and track their cellular and organismal distribution in development or disease. The biosynthesis of glycans containing specific residues can be visualized by the incorporation of functional groups that can be used to append reporter groups. Both the Staudinger ligation and the Huisgen 1,3-dipolar cycloaddition reaction of azides with alkynes (often referred to as click chemistry) have been employed in biological environments (Figure 7c) (51) . A major issue in these transformations is the rate of reaction, which determines the labeling time and sensitivity. Attempts to increase reaction efficiency have focused on the azide-alkyne 1,3-dipolar cycloaddition. Although this reaction can be catalyzed by copper(I), these conditions are deleterious to cells. Using a more reactive, strained difluorinated cyclooctyne partner circumvents the requirement for copper catalysis (Figure 14a) . A variety of sugar building blocks bearing azido groups can be incorporated, including derivatives corresponding to sialic acid, N-acetylgalactosamine (GalNAc), GlcNAc, and fucose (152). The azide moiety can then undergo reaction with an alkyne bearing a fluorophore or other reporter group. The advantages of this labeling strategy are illustrated by its use in visualizing glycans in whole animals. Specifically, zebrafish embryos were incubated with GalNAz to generate glycans that bear azide groups. The GalNAz residues could be visualized by their ability to undergo a cycloaddition reaction with fluorophorelabeled cyclooctynes. By using two different fluorescent tags, changes in O-glycosylation during the course of zebrafish development could be observed. An alternative approach for glycan tagging in cells takes advantage of mild oxidation, which occurs at endogenous sialic acid residues, to afford an aldehyde at the C7 Strategies for visualizing glycans can be achieved by (a) metabolic incorporation of a sugar bearing a latent reactive group (e.g., azide) or (b) chemical modification of endogenous glycans to introduce a chemical handle that can be functionalized with fluorophores or other reporter molecules. Abbreviation: Ac, acetate.
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position (158) . Aniline-catalyzed oxime ligation with an aminooxy-modified molecular tag provides a chemical handle that can be used for visualization or tracking of glycans (Figure 14b ). This method is complementary to metabolic labeling; not all systems will tolerate the mild oxidation step, but the labeling can be done on a faster timescale. Together, these results emphasize the advances that have been made in strategies to observe glycan production and turnover.
CONCLUSION
Emil Fischer, a pioneer in recognizing the critical role of chemistry in understanding carbohydrates, stated in his Nobel Lecture (159), ". . . the chemical enigma of Life will not be solved until organic chemistry has mastered another, even more difficult subject, the proteins, in the same way as it has mastered the carbohydrates." Though one can only admire Fischer, today his statement appears ironic, especially given the formidable challenges of elucidating glycan function that remain. These challenges are being met by an assemblage of interdisciplinary approaches.
Research in chemical glycobiology is driving discovery by offering new approaches and tools to explore and exploit the functions of glycans.
SUMMARY POINTS
1. Glycans are involved in myriad specific molecular and cellular events from development to disease.
2. The field of glycobiology demands the development of new approaches to elucidate glycan function. Chemical biology approaches provide critical tools and strategies that can be used to probe or perturb glycan function.
3. The synthesis of glycans and the development of chemoselective reactions have greatly expanded the repertoire of oligosaccharides and glycoconjugates available.
4. Glycan and lectin arrays have emerged as valuable platforms to interrogate protein-glycan interactions.
5. The biosynthesis of glycans can be exploited to introduce new functionality that can be used for analysis or imaging.
6. Inhibitors, both rationally designed glycomimetics and small molecules, are promising new tools with which to investigate and interfere with the biological roles of glycans.
7. Synthetic multivalent ligands are valuable tools for investigating the low-affinity interactions characteristic of glycan-binding events.
FUTURE ISSUES
1. The continued development of new strategies and approaches in both chemical and chemoenzymatic syntheses will provide increased access to complex glycans. Methods are needed to assemble less explored glycans, including sulfated oligosaccharides and the unique glycans found in microbes and other pathogens.
2. Glycans lack functional group handles that can be used to install fluorophores or other reporters to directly assess binding or enzyme-catalyzed modification reactions. Thus, new strategies for devising high throughput are needed to identify and engineer enzymes for the synthesis of glycans and to promote the discovery of probes of glycan function.
3. Methods for monitoring glycan degradation are needed, as this process is critical for human health and has ramifications for harvesting energy from plant cell walls. 
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